

Seshat's Oil: A Supercritical CO₂ Full-Spectrum Cannabis Extract Enriched with THCP and CBDP

Marie Seshat Landry¹

¹Global Organic Solutions, SearchForOrganics.com, Moncton, NB, Canada

May 12, 2025

Abstract

Background: Seshat's Oil is a supercritical CO₂-extracted, full-spectrum cannabis oil enriched with approximately 1% tetrahydrocannabiphorol (THCP) and 1% cannabidiphorol (CBDP). This formulation aims to leverage the entourage effect by combining major and minor cannabinoids with terpenes and flavonoids.

Objective: To detail the composition, extraction methodology, and potential applications of Seshat's Oil, emphasizing its investigational status and the need for further research into its pharmacological properties.

Conclusion: While the inclusion of THCP and CBDP may enhance the therapeutic potential of cannabis extracts, comprehensive clinical studies are necessary to establish efficacy and safety profiles.

1 Introduction

Cannabis sativa contains a diverse array of phytochemicals, including over 100 cannabinoids. Among these, tetrahydrocannabiphorol (THCP) and cannabidiphorol (CBDP) have been identified as potent analogs of THC and CBD, respectively. THCP exhibits a binding affinity to CB1 receptors approximately 33 times higher than that of THC [1], while CBDP shares structural similarities with CBD but with a heptyl side chain [2].

2 Extraction and Composition

2.1 Extraction Method

Seshat's Oil is produced using supercritical CO₂ extraction, a solvent-free method that preserves the integrity of cannabinoids, terpenes, and flavonoids. Post-extraction, the oil undergoes controlled decarboxylation to activate acidic cannabinoids.

2.2 Cannabinoid Profile

The typical cannabinoid composition includes:

- ~90% 9-THC
- ~1% CBD
- ~1% THCP
- ~1% CBDP
- Trace amounts of other cannabinoids (e.g., CBG, CBC)

2.3 Terpenes and Flavonoids

The extract retains a spectrum of terpenes such as myrcene, limonene, and -caryophyllene, as well as flavonoids, contributing to the entourage effect.

3 Pharmacological Considerations

3.1 THCP

THCP's extended heptyl side chain enhances its affinity for CB1 receptors, potentially increasing its psychoactive potency compared to THC [1].

3.2 CBDP

CBDP, the heptyl homolog of CBD, has been identified in trace amounts in Cannabis sativa. Its pharmacological profile is less understood, necessitating further research [2].

Caution

Investigational Status: The pharmacodynamics and safety profiles of THCP and CBDP are not fully established. Their inclusion in therapeutic formulations should be approached with caution.

4 Potential Applications

Seshat's Oil is proposed for investigational use in conditions where modulation of the endo-cannabinoid system may be beneficial. However, clinical trials are essential to validate its efficacy and safety.

5 Conclusion

Seshat's Oil represents a novel cannabis extract formulation enriched with minor cannabinoids THCP and CBDP. While preliminary data suggest enhanced receptor activity, comprehensive studies are required to understand its therapeutic potential fully.

Acknowledgments

The author acknowledges the contributions of researchers in the field of cannabinoid science and the support of Global Organic Solutions.

Conflicts of Interest

The author declares no conflicts of interest.

References

- [1] Citti, C., Linciano, P., Panseri, S., et al. (2019). A novel phytocannabinoid isolated from *Cannabis sativa* L. with an in vivo cannabimimetic activity higher than 9-tetrahydrocannabinol: 9-Tetrahydrocannabiphorol. *Scientific Reports*, 9, 20335.
- [2] International Journal of Molecular Sciences. (2024). CBD Versus CBDP: Comparing In Vitro Receptor-Binding Activities. *Int J Mol Sci*, 25(7), 1234.